With Perservative, Stabilizer, Or An Additional Active Ingredient Patents (Class 514/263.31)
-
Publication number: 20130045162Abstract: Methods for prevention, treatment or inhibition of the growth or metastasis of cancer cells in a subject are disclosed. One method comprises the step of administering to the subject a therapeutically effective amount of tumor associated antigen binding ligand-coated planetary ball milled (PBM) nanoparticles containing a cytotoxic agent.Type: ApplicationFiled: August 8, 2012Publication date: February 21, 2013Applicant: MOREHOUSE SCHOOL OF MEDICINEInventors: James W. Lillard, JR., Shailesh Singh, Rajesh Singh
-
Publication number: 20130029989Abstract: The present invention relates to novel compositions and therapeutic methods for the treatment of pain, in particular neuropathic, ischemic, muscle, arthritic or multiple sclerosis pain. The compositions include a combination of an alpha2-adrenergic agonist or a nitric oxide donor combined with a phosphodiesterase (PDE) or a phosphatidic acid (PA) inhibitor, which have been found to act together synergistically to provide effective treatment for pain, especially when administered topically.Type: ApplicationFiled: April 13, 2011Publication date: January 31, 2013Applicant: The Royal Institution for the Advancement of Learning/McGill UniversityInventors: Terence Coderre, Andre Laferriere, Vaigunda Ragavendran Jegadeesan
-
Publication number: 20130018061Abstract: A method for improving exercise performance and recovery from exercise is provided. The method involves administration of a specific ratio of caffeine and L-theanine. The method is useful for any individual participating in exercise and may be particularly beneficial for individuals accustomed to regular, high caffeine intake.Type: ApplicationFiled: July 12, 2011Publication date: January 17, 2013Applicant: Northern Innovations and Formulations CorpInventors: Raza Bashir, Craig Wissent
-
Publication number: 20130012470Abstract: Novel compositions comprising viral fusion inhibition compounds and viral replication inhibition compounds as well as methods of their use are disclosed. The novel compositions are useful, inter alia, in the prevention, inhibition and/or treatment of Dengue Fever (DF) or Dengue Hemorrhagic Fever (DHF).Type: ApplicationFiled: July 7, 2011Publication date: January 10, 2013Applicant: Humanitas Technology, LLCInventors: John Schlafer Colman, Luis Ramon Romero
-
Publication number: 20120328695Abstract: Pharmaceutical compositions and methods for the treatment of chronic fatigue in human patients comprising a central nervous system (CNS) stimulant in a daily low-dosage amount in combination with therapeutically effective daily amounts of micronutrients, comprising acetyl L-carnitine, L-tyrosine, N-acetyl cysteine, and alpha-lipoic acid. The CNS and micronutrient components may be in an oral dosage composition containing a low dosage amount of CNS stimulant such as about 2.5 mg methylphenidate HCl together with about 60-250 mg acetyl L-carnitine, 50-200 mg L-tyrosine, 60-250 mg N-acetyl cysteine, and 25-100 mg alpha-lipoic acid.Type: ApplicationFiled: June 22, 2012Publication date: December 27, 2012Inventor: Jon D. Kaiser
-
Publication number: 20120308519Abstract: Described herein are 4-methyl-piperazine-1-carbothioic acid amide derivatives and analogs, as well as compositions containing the same, for the treatment or prophylaxis of viral infections and diseases associated therewith, particularly those viral infections and associated diseases caused by hemorrhagic fever viruses, such as Arenaviruses.Type: ApplicationFiled: December 29, 2011Publication date: December 6, 2012Applicant: Siga Technologies, Inc.Inventors: Sean M. Amberg, Dongcheng Dai, Tove C. Bolken, Dennis E. Hruby
-
Patent number: 8318201Abstract: (wherein Y1 and Y2 may be the same or different and each represents a hydrogen atom, halogen or lower alkyl; and Z and A may be the same or different and each represents substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl) The present invention provides, for example, a method for stabilization of a diarylvinylene compound such as a compound represented by the above formula (I) or the like, or a pharmaceutically acceptable salt thereof in a solid formulation containing the diarylvinylene compound or the pharmaceutically acceptable salt thereof, which comprises allowing an inorganic substance and/or a colorant to exist in the solid formulation, and the like.Type: GrantFiled: September 29, 2004Date of Patent: November 27, 2012Assignee: Kyowa Hakko Kirin Co., Ltd.Inventors: Akihiro Uchida, Yasuhiro Ishikawa, Yasuhiko Ueno, Kiichiro Kaji, Masaharu Aimoto, Naoki Kaneko
-
Publication number: 20120277179Abstract: The disclosure relates to an edible energy composition that provides physical and mental benefits when ingested.Type: ApplicationFiled: May 14, 2012Publication date: November 1, 2012Applicant: BioClinical Development Inc.Inventor: Manoj Bhargava
-
Publication number: 20120264698Abstract: Dopamine reuptake inhibitors, and their analogs, are disclosed for treating and delaying the progression of autoimmune diseases.Type: ApplicationFiled: October 5, 2011Publication date: October 18, 2012Inventors: Hao Chen, Alexel Miagkov, Lisa Leary, Ming Liu, Qi Su
-
Publication number: 20120252824Abstract: The present specification discloses compositions comprising a plurality of therapeutic compound having antitussive activity and methods and uses for treating a coughing condition with such compositions.Type: ApplicationFiled: April 13, 2012Publication date: October 4, 2012Inventors: John Brew, Robin Mark Bannister
-
Publication number: 20120237570Abstract: The present invention relates to methods and compositions for reducing distress dysfunction, including emotional and physical distress. The invention entails co-administration of at least one Receptor Switcher and at least one Endorphin Enhancer. Additionally, at least one Synergistic Enhance and/or at least one Exogenous Opioid are also administered to enhance or prolong the therapeutic effects.Type: ApplicationFiled: April 30, 2012Publication date: September 20, 2012Inventors: Steven Crain, William E. Crain, Stanley M. Crain, Michael Crain
-
Publication number: 20120225144Abstract: An extraction method for extracts of Geranium or Pelargonium with improved methylhexaneamine content is provided. The method involves separating the oil phase from the aqueous phase; concentrating the aqueous phase; purifying the oil phase; and recombining the resulting material. Additionally, extracts of Geranium or Pelargonium prepared by the extraction method are provided. The extracts are useful in compositions, for example as dietary supplements, and for appetite suppression.Type: ApplicationFiled: March 2, 2011Publication date: September 6, 2012Applicant: Northern Innovations and Formulations Corp.Inventors: James Akrong, Shawn Shirazi, Vincent Scalisi, Jason Peters
-
Publication number: 20120213758Abstract: The present invention relates to a genus of biaryl compounds containing at least one further ring. The compounds are PDE4 inhibitors useful for the treatment and prevention of stroke, myocardial infarct and cardiovascular inflammatory diseases and disorders.Type: ApplicationFiled: April 27, 2012Publication date: August 23, 2012Applicant: DeCODE Genetics enfInventors: Jasbir SINGH, Mark E. GURNEY, Alex BURGIN, Alexander KISELYOV, Munagala RAO, Timothy HAGEN
-
Patent number: 8236810Abstract: The invention 8-aminothioxanthines and the derivatives of formula I wherein the various R groups and substituents are comprised of a number of different (C1-C10)-alkyl, cycloalkyl, aryl, alkene, alkyne, etc. groups and derivatives thereof which are hereinafter more specifically defined for the treatment of metabolic disorders such as type-2 diabetes, hyperglycemia, arteriosclerotic diseases and the like.Type: GrantFiled: January 11, 2007Date of Patent: August 7, 2012Assignee: Sanofi-Aventis Deutschland GmbHInventors: Karl Schoenafinger, Gerhard Jaehne, Elisabeth Defossa, Guenter Billen, Christian Buning, Georg Tschank, Ulrich Werner
-
Patent number: 8236768Abstract: The disclosure provides novel topical antiviral pharmaceutical compositions comprising one or more antiviral compounds and 2-deoxy-D-glucose in the form of lip-balms, creams and ointments. A specific embodiment discloses a lip-balm composition comprising acyclovir and 2-deoxy-D-glucose.Type: GrantFiled: October 2, 2009Date of Patent: August 7, 2012Assignee: 3B Pharmaceuticals, Inc.Inventors: Darby C. Brown, Kristen A. Brown
-
Publication number: 20120184519Abstract: The invention includes compositions and methods for regulating PI3K p110 delta as an anti-retroviral therapy. The invention includes inhibiting p110 delta, a component of PI3K p110 delta signaling pathway, or any combination thereof in a cell as an anti-retroviral therapeutic approach for treating a retroviral infection, for example HIV. The invention includes a method of modulating PI3K p110 delta in a cell infected with a retrovirus by contacting the cell with an effective amount of a composition comprising an inhibitor of PI3K p110 delta.Type: ApplicationFiled: March 12, 2012Publication date: July 19, 2012Inventors: Peter D. Katsikis, Alina C. Boesteanu, Martin Turner
-
Publication number: 20120171302Abstract: The invention provides compositions for inhibiting a redox-sensitive GTPase protein, including a Rho or Rab family GTPase, comprising an effective amount of a redox-sensitive purine compound and an effective amount of a redox agent. The invention further provides methods of inhibiting a redox-sensitive GTPase protein, including a Rho or Rab family GTPase, by administering compositions of the invention. Methods of screening for compounds that inhibit a redox-sensitive GTPase protein, including compounds that target and inhibit Rho or Rab family GTPases, are further provided.Type: ApplicationFiled: December 21, 2011Publication date: July 5, 2012Applicant: The Board of Regents, The University of Texas SystemInventor: Jongyun Heo
-
Publication number: 20120171308Abstract: The present application describes an antioxidant complex having a synergistic effect between its ingredients. Said mixture comprises: a) vitamin E and/or derivatives thereof; b) green tea extract and/or derivatives thereof; and c) cacao extract. Examples of cosmetic and pharmaceutical compositions comprising said antioxidant complex and a physiologically acceptable carrier are also described. The antioxidant complex of the present invention, as well as the aforementioned compositions, aid in preventing and protecting against cell and skin damages resulting from the action of free radicals, and also provide DNA, protein and cell membrane protection.Type: ApplicationFiled: October 30, 2009Publication date: July 5, 2012Applicant: Natura Cosmeticos S.A.Inventors: Patricia Da Lúz Moreira, Kelen Fabiola Arroteia, Cintia Rosa Ferrari, Adriano Tadeu Siqueira Jorge, Juliana Carvalhães Lago, Jean Luc Gesztesi, Philip Leite Ribeiro
-
Publication number: 20120132204Abstract: An inhaler includes a first body member and a second body member fit closely together to form an inhaler body, and an outlet. The first body member has a medicament chamber containing a unit dose of powdered medicament. A seal such as a foil strip seals the medicament chamber and extends outwardly of the inhaler body. In use, one end of the seal can be grasped by a user and withdrawn, fully or partially, from the inhaler body, to release the powdered medicament from the medicament chamber. The second body member includes a medicament collection well in which the medicament is collected upon its release from the medicament chamber. The medicament collection well forms part of an airway connecting into the outlet. In use, air can be drawn by inhalation at the outlet to entrain the powder medicament in the collection well for inhalation by a user.Type: ApplicationFiled: February 9, 2012Publication date: May 31, 2012Applicant: INNOVATA BIOMED LIMITEDInventors: Samuel W. Lucking, Glen P. Martyn
-
Publication number: 20120111324Abstract: The present disclosure relates to systems, methods, and formulations for the pulmonary administration of one or more therapeutic agents, in dry powder form, in a single, large dose quantity. These formulations, methods, and systems are useful in the treatment of patients suffering from toxic or harmful gas exposure, such as nerve gas exposure, as well as in the treatment of patients suffering from diseases of the pulmonary system, including tuberculosis, cystic fibrosis, and chronic obstructive pulmonary disease (COPD).Type: ApplicationFiled: October 22, 2008Publication date: May 10, 2012Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Edward R. Kraft, Stephen L. Hoskins, Perenlei Enkhbaatar, Daniel L. Traber
-
Publication number: 20120107300Abstract: Cannabinoid compositions and methods of administering said cannabinoid compositions are disclosed. The cannabinoid compositions disclosed herein include compounds which have been strategically selected to eliminate, or least mitigate, one of the negative side effects associated with consuming cannabinoids. A daytime formula includes compounds aimed at nullifying the negative side effects that cannabinoid consumption has on a patient's daily operations and activities. A nighttime formula includes compounds aimed at nullifying the negative side effects that cannabinoid consumption has a patient's sleep.Type: ApplicationFiled: November 1, 2010Publication date: May 3, 2012Inventor: Jeffrey Nathan Schirripa
-
Publication number: 20120088773Abstract: A method and composition is herein described to modulate the circadian rhythm to effect summer metabolism and the metabolic syndrome. The method entails the once daily, timed ingestion of a dopamine precursor or a dopamine agonist, receptor primed with caffeine, and vitamin D3.Type: ApplicationFiled: October 6, 2010Publication date: April 12, 2012Inventor: Ronald J. Thompson
-
Publication number: 20120083473Abstract: Provided herein are methods for treating certain conditions, including fibrosis, inflammatory, and autoimmune conditions, with conjugated compounds having Toll-like receptor modulatory activity.Type: ApplicationFiled: September 20, 2011Publication date: April 5, 2012Inventors: Johanna Holldack, Alberto Mantovani, Antonio Sica, Nadia Passini, Roberto Maj, Alcide Barberis
-
Publication number: 20120064032Abstract: The present invention is directed to certain hydroxamate derivatives that are useful in the treatment of hepatitis C. These compounds are also inhibitors of histone deacetylase and are therefore useful in the treatment of diseases associated with histone deacetylase activity. Pharmaceutical compositions and processes for preparing these compounds are also disclosed.Type: ApplicationFiled: August 12, 2011Publication date: March 15, 2012Applicant: Pharmacyclics, Inc.Inventors: Erik J. Verner, Martin Sendzik, Chitra Baskaran, Joseph J. Buggy, James Robinson
-
Publication number: 20120053142Abstract: The invention relates to compositions comprising at least one xanthine compound, preferably further comprising at least one agent which acts on capillary circulation and/or at least one natural moisturizing agent, which can be used to treat, or to reduce and/or minimize the appearance of, defects such as dark circles, bags and/or puffiness around eyes.Type: ApplicationFiled: November 3, 2011Publication date: March 1, 2012Applicant: L'Oreal S.A.Inventor: Isabelle TERRISSE
-
Publication number: 20120045531Abstract: Provided are methods of treating cellulite, the methods comprising applying to skin in need of cellulite treatment a composition comprising paulownin or an extract of Paulownia wood.Type: ApplicationFiled: August 17, 2011Publication date: February 23, 2012Inventors: Khalid Mahmood, Thierry Oddos
-
Publication number: 20120010225Abstract: The present invention provides pharmaceutical compositions, which are useful for treatment of depression and the like, and which comprises a compound having an adenosine A2A receptor antagonistic activity such as (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione or a pharmaceutically acceptable salt thereof and an antidepressant drug (for example, a tricyclic antidepressant, a tetracyclic antidepressant, a selective serotonin reuptake inhibitor, a selective noradrenalin reuptake inhibitor, a dopamine reuptake inhibitor, a serotonin-noradrenalin reuptake inhibitor, monoamine oxidase inhibitor, a 5-HT2 antagonist or the like), and the like.Type: ApplicationFiled: September 16, 2011Publication date: January 12, 2012Applicant: KYOWA HAKKO KIRIN CO., LTD.Inventors: Hiroshi Kase, Minoru Kobayashi, Shizuo Shiozaki, Akihisa Mori, Naoki Seno
-
Publication number: 20110275561Abstract: The present invention relates to the finding that certain DPP-4 inhibitors are particularly suitable for treating and/or preventing metabolic diseases, particularly diabetes, in patients with insufficient glycemic control despite a therapy with an oral and/or a non-oral antidiabetic drug.Type: ApplicationFiled: October 15, 2009Publication date: November 10, 2011Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Eva Ulrike Graefe-Mody, Thomas Klein, Michael Mark, Hans-Juergen Woerle
-
Publication number: 20110269717Abstract: The instant invention describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The invention includes compositions and methods based on modulating angiotensin activity to stimulate or activate the formation of new nerve cells.Type: ApplicationFiled: November 30, 2010Publication date: November 3, 2011Applicant: BrainCells Inc.Inventors: Carrolee BARLOW, Todd A. Carter, Kai Treuner, Kym I. Lorrain, Corey R. Seehus
-
Publication number: 20110245323Abstract: The present invention encompasses compositions and compounds as well as methods of their use for the regulation of a VEGF-induced tissue response. A VEGF-induced tissue response may include angiogenesis, inflammation, increased vascular permeability, increased vascular leak, hemorrhage, or mucus metaplasia. As such, the present invention encompasses methods of treating diseases where a VEGF-induced tissue response is part of the disease's clinical presentation. Specifically, the present invention provides compounds and compositions as well as methods for treating acute lung injury (ALI), acute respiratory distress syndrome (ARDS), asthma, chronic obstructive pulmonary disease (COPD), obstructive sleep apnea (OSA), idiopathic pulmonary fibrosis (IPF), tuberculosis, pulmonary hypertension, pleural effusion, and lung cancer.Type: ApplicationFiled: March 31, 2011Publication date: October 6, 2011Inventor: Jack Elias
-
Publication number: 20110217252Abstract: It is described the use of propionyl L-carnitine for treating disturbances of the skin such as cellulite.Type: ApplicationFiled: November 5, 2009Publication date: September 8, 2011Applicant: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.Inventor: Aleardo Koverech
-
Publication number: 20110201675Abstract: The invention includes compositions and methods of treatment of cancers susceptible to treatment with nucleotide analog chemotherapeutic agent, including cancers in which nucleotide analog resistant tumors have developed, including identifying a subject having cancer susceptible to treatment with a nucleotide analog chemotherapeutic agent and a mitotic disruptor/polo-like kinase (Plk) pathway inhibitor to a subject; and monitoring the subject for a reduction or stabilization of at least one sign or symptom of cancer.Type: ApplicationFiled: April 17, 2008Publication date: August 18, 2011Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: Antonio Jimeno, Manuel Medina Hidalgo
-
Patent number: 7998507Abstract: Nanoparticulate compositions comprising at least one poorly soluble MAP kinase inhibitor and at least one surface stabilizer are described. The nanoparticulate compositions have an average particle size of less than about 2000 nm. The invention also describes methods of making and using such compositions.Type: GrantFiled: December 7, 2005Date of Patent: August 16, 2011Assignee: Elan Pharma International Ltd.Inventors: H. William Bosch, Greta G. Cary, Douglas C. Hovey, Rajeev A. Jain, Laura J. Kline, Elaine Merisko-Liversidge, Kevin D. Ostrander, Niels P. Ryde, Stephen B. Ruddy
-
Publication number: 20110195425Abstract: Systems and methods for diagnosing parasite infections. According to at least one embodiment of a stabilizing system of the present disclosure, a stabilizing system comprises a stabilizing agent useful to completely or substantially prevent degradation or inactivation of a diagnostic marker for a parasite infection in a body fluid comprising the diagnostic marker and a detection agent capable of detecting the diagnostic marker.Type: ApplicationFiled: October 18, 2010Publication date: August 11, 2011Inventors: Richard H. Selinfreund, Rakesh Vig, Richard P. Gill
-
Publication number: 20110195398Abstract: Systems and methods for detecting insulin resistance biomarkers. At least one embodiment of a system of the present disclosure comprises a stabilizing agent useful to completely or substantially prevent degradation or inactivation of a diagnostic marker for insulin resistance or glucose intolerance in a body fluid comprising the diagnostic marker, and a detection agent capable of detecting the diagnostic marker.Type: ApplicationFiled: October 18, 2010Publication date: August 11, 2011Inventors: Richard H. Selinfreund, Rakesh Vig, Richard P. Gill
-
Publication number: 20110195397Abstract: Drink mixture for the stabilization of diagnostic biomarkers. In at least one embodiment of an ingestible beverage useful to stabilize a diagnostic marker, the rinse comprises a stabilizing agent useful to completely or substantially prevent degradation or inactivation of a diagnostic marker in saliva, and a liquid.Type: ApplicationFiled: October 18, 2010Publication date: August 11, 2011Inventors: Richard H. Selinfreund, Rakesh Vig, Richard P. Gill
-
Publication number: 20110195403Abstract: Systems and methods for fertility analysis. In at least one embodiment of a system of the present disclosure, the system comprises a stabilizing agent useful to completely or substantially prevent degradation or inactivation of a diagnostic marker for fertility in a body fluid comprising the diagnostic marker, and a detection agent capable of detecting the diagnostic agent. In an exemplary embodiment, the stabilizing agent may be selected from the group consisting of a protease inhibitor, a DNase inhibitor, and a RNase inhibitor.Type: ApplicationFiled: October 18, 2010Publication date: August 11, 2011Inventors: RICHARD H. SELINFREUND, Rakesh Vig, Richard P. Gill
-
Publication number: 20110189275Abstract: Cocrystals of pterostilbene are disclosed, including: pterostilbene:caffeine cocrystal, pterostilbene:carbamazepine cocrystal, pterostilbene:glutaric acid cocrystal, and pterostilbene:piperazine cocrystal. The pterostilbene:caffeine cocrystal is polymorphic. Forms I and II of the pterostilbene:caffeine cocrystal are disclosed. The therapeutic uses of the pterostilbene cocrystals and of pharmaceutical/nutraceutical compositions containing them are also disclosed. The disclosure sets out various methods of making and characterizing the pterostilbene cocrystals.Type: ApplicationFiled: July 30, 2010Publication date: August 4, 2011Inventors: Nathan C. SCHULTHEISS, Sarah J. Bethune
-
Publication number: 20110123651Abstract: A nutritional beverage or drink is provided having resveratrol mixed with water, suspended in a liquid suspension system. One or more of quercetin, catechins, antioxidants, energy agents, sweeteners, preservatives, pH balancing ingredients, and coloring agents may also be included. A process is provided for preparing a dietary supplement drink in a liquid suspension, comprising mixing water in a suspension system with resveratrol. The process may also include adding one or more of quercetin, catechins, antioxidants, energy agents, sweeteners, preservatives, acidulants, and coloring agents. The nutritional beverage or drink may also be modified by using pure water that has nanosized water clusters therein, as well as mixing into the liquid suspension nanoparticles of resveratrol and/or one or more of the above ingredients to enhance the bioavailability of the ingredients. The compositions may be used to treat diseases and bodily malfunctions.Type: ApplicationFiled: May 20, 2010Publication date: May 26, 2011Inventors: Thomas E. Mower, Charles Jeffery Brady
-
Publication number: 20110104083Abstract: Cosmetic compositions comprising therapeutic agents for the treatment of various eye conditions and methods of use are described. In particular, the invention provides cosmetic compositions comprising ophthalmic therapeutic agents in combination with a muscle fasciculating agent for application to the outer surface of the upper eyelid, perimeter of the eyelid and/or eyelashes thereby causing transfer of the therapeutic agents into the vascular network within the eyelid for delivery into all parts of the eye, including the posterior segments of the eye, the eyelid glands, conjuctiva and periocular tissue.Type: ApplicationFiled: October 29, 2010Publication date: May 5, 2011Inventors: Padma NANDURI, T. Aaron Dyer
-
Publication number: 20110105419Abstract: The invention relates to the use of small and ultra small quantities of bi- and oligo-nuclear forms of the coordination compounds of d-metals in the form of drugs or agents for enhancing the therapeutic efficiency of pharmacological substances.Type: ApplicationFiled: February 16, 2009Publication date: May 5, 2011Inventors: Mark Borisovich Balazovsky, Viktor Georgievich Antonov, Alexandr Nikolaevich Belayev, Alexei Viktorovich Eremin
-
Patent number: 7935367Abstract: A composition and method for promoting weight loss through the mutual and simultaneously to promotion lipolysis, the expenditure of energy stored in the body as fat, the inhibition of lipolysis as well as affording the body of an individual protection from reactive oxygen species resulting from the ?-oxidation of fats. The composition comprises at least a lipolytic substance, a thermogenic substance, a substance to inhibit the reformation of triglycerides in the bodily tissues of an individual and an antioxidant.Type: GrantFiled: March 8, 2007Date of Patent: May 3, 2011Assignee: HHC Formulations Ltd.Inventors: Marvin Heuer, Ken Clement, Shan Chaudhuri
-
Publication number: 20110086138Abstract: Disclosed are bitter alkaloid-containing consumables comprising bitter blockers for a reduced alkaloid-derived bitterness and methods of forming said consumables.Type: ApplicationFiled: May 19, 2009Publication date: April 14, 2011Inventors: Zhonghua Jia, Kimberley Gray, Rajesh Venkata Potineni
-
Patent number: 7914831Abstract: The invention provides compositions containing a fraction isolated or derived from hops and a methylxanthine. The invention additionally provides compositions containing a fraction derived from hops and a curcuminoid. The invention also provides methods of using such compositions to reduce inflammation.Type: GrantFiled: February 27, 2004Date of Patent: March 29, 2011Assignee: Metaproteomics, LLCInventors: John G. Babish, Matthew L. Tripp, Jeffrey S. Bland
-
Patent number: 7915269Abstract: Methods for concomitant administration of colchicine together with one or more second active agents, e.g., ketoconazole and ritonavir, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for concomitant administration of colchicine together with second active agents are also provided.Type: GrantFiled: August 18, 2010Date of Patent: March 29, 2011Assignee: AR Holding Company, Inc.Inventor: Matthew W. Davis
-
Patent number: 7906519Abstract: Methods for concomitant administration of colchicine together with one or more second active agents, e.g., ketoconazole and ritonavir, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for concomitant administration of colchicine together with second active agents are also provided.Type: GrantFiled: August 18, 2010Date of Patent: March 15, 2011Assignee: AR Holding Company, Inc.Inventor: Matthew W. Davis
-
Publication number: 20110052694Abstract: Described herein are microneedle drug delivery systems comprising a pharmaceutical compositions comprising pharmaceutically active agents (e.g., cannabidiol and prodrugs of cannabidiol) and microneedle arrays suitable for local and systemic delivery of the active agent to a mammal. Also described herein are methods of using a microneedle transdermal or topical drug delivery systems comprising pharmaceutical compositions, comprising cannabidiol and prodrugs of cannabidiol, and microneedle arrays in the treatment disease, including pancreatitis and pancreatic cancer.Type: ApplicationFiled: August 31, 2010Publication date: March 3, 2011Applicant: ALLTRANZ INC.Inventors: Audra Lynn Stinchcomb, Stan Lee Banks, Miroslaw Jerzy Golinski, Jeffery Lynn Howard, Dana Carmel Hammell
-
Publication number: 20110034486Abstract: The invention relates to a cosmetic, dermatological or pharmaceutical preparation, containing one, two or more compounds of formula (I) and/or a pharmaceutically acceptable salt of a compound of this type, (i) for use in a method for preventing, treating or reducing cellulite, and/or (ii) in an adequate quantity to reduce the lipid quantity contained in subcutaneous fat tissue, and/or to inhibit the differentiation of preadipocytes, and/or to inhibit the lipogenesis in adipocytes, wherein the radicals R1 to R8, independently of one another, signify hydrogen, hydroxy or C1-C4-alkoxy, and/or two adjacent radicals together form a methylenedioxy group.Type: ApplicationFiled: August 3, 2010Publication date: February 10, 2011Applicant: SYMRISE GmbH & Co., KGInventors: Imke Meyer, Oskar Koch, Nadine Hillebrand, Martina Herrmann, Holger Joppe
-
Patent number: 7879864Abstract: Compounds for the treatment of elevated blood glucose levels and the physiological and metabolic disorders arising therefrom are disclosed which are inhibitors of the enzyme dipeptidyl peptidase IV (DDP-IV) and comprise novel substituted bicyclic 8-pyrrolidinoxanthines of formula I and their derivatives: wherein the various R-groups are defined herein. These compounds may be combined with other secondary active compounds which also are effective in the treatment of said disorders and the disease states or physiological manifestations arising therefrom.Type: GrantFiled: February 13, 2007Date of Patent: February 1, 2011Assignee: Sanofi-Aventis Deutschland GmbHInventors: Karl Schoenafinger, Gerhard Jaehne, Elisabeth Defossa, Christian Buning, Georg Tschank, Ulrich Werner
-
Publication number: 20110020471Abstract: Erythrocyte ATP-release modulators and composition and methods for their use to potentiate serum glucose clearance and vasodilation; methods for prophylactic or palliative therapy of glucose processing or vascular disorders; processes for preparing the modulators and compositions comprising them; and kits therefor.Type: ApplicationFiled: September 23, 2009Publication date: January 27, 2011Applicants: Wayne State University, Board of Directors of Michigan State UniversityInventors: Dana Spence, Gavin Edmund Reid